Pacira reports Q1 EPS 62c, consensus 62c

Reports Q1 revenue $167.1M, consensus $165.35M.”Sales are off to a solid start for all three of our trusted, opioid-sparing products and we remain sharply focused on driving accelerated growth in 2025 and beyond,” said Frank D. Lee, chief executive officer of Pacira BioSciences. “We are pleased with the progress we are making advancing the launch of EXPAREL in two new lower extremity nerve block indications, and we are receiving positive market receptivity across all sites of care. We are also preparing for a significant growth catalyst ahead with the implementation of separate Medicare reimbursement for EXPAREL at average sales price plus 6 percent in outpatient settings beginning in January 2025. We believe this important reimbursement milestone will expand patient access to EXPAREL and drive greater utilization in outpatient procedures.” “Our confidence in Pacira’s future remains steadfast and the $150 million stock buyback announced today underscores our belief in our team, products, and growth outlook,” added Mr. Lee